KYTX — Kyverna Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $536.10m
- $281.90m
Annual cashflow statement for Kyverna Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26.4 | -28.9 | -60.4 | -127 | -161 |
| Depreciation | |||||
| Non-Cash Items | 8.1 | 2.06 | 2.83 | 3.24 | 6.87 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -4.49 | -10.3 | 3.42 | 7.86 | -1.08 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -22.2 | -36.1 | -52.4 | -114 | -154 |
| Capital Expenditures | -1.29 | -0.768 | -0.621 | -2.21 | -1.13 |
| Purchase of Fixed Assets | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | 0 | -13.3 | -8.16 | -159 | 41.1 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.29 | -14.1 | -8.79 | -161 | 40 |
| Financing Cash Flow Items | — | — | -1.65 | -3.36 | -0.619 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 72.5 | 11.9 | 58.1 | 337 | 141 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 49.1 | -38.3 | -3.08 | 62 | 27.5 |